Use of cartilage derived from murine induced pluripotent stem cells for osteoarthritis drug screening

Arthritis and Rheumatology

Volumn 66, Issue 11, 2014, Pages 3062-3072

  Willard, Vincent P ^a   Diekman, Brian O ^a   Sanchez Adams, Johannah ^a   Christoforou, Nicolas ^b,c   Leong, Kam W ^b,d   Guilak, Farshid ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c KHALIFA UNIVERSITY   (United Arab Emirates)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE 1; AGGRECANASE 2; COLLAGENASE 3; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GELATINASE B; GLYCOSAMINOGLYCAN; ILOMASTAT; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE; PROSTAGLANDIN E2; ANTIRHEUMATIC AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; BIOCHEMICAL COMPOSITION; CARTILAGE CELL; CELL SUSPENSION; CONTROLLED STUDY; DRUG SCREENING; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MICROENVIRONMENT; MOUSE; NONHUMAN; OSTEOARTHRITIS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; YOUNG MODULUS; ANIMAL; C57BL MOUSE; CARTILAGE; CELL CULTURE; CELL DIFFERENTIATION; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; ANTIRHEUMATIC AGENTS; CARTILAGE; CELL DIFFERENTIATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; GLYCOSAMINOGLYCANS; HIGH-THROUGHPUT SCREENING ASSAYS; IN VITRO TECHNIQUES; INTERLEUKIN-1ALPHA; MICE; MICE, INBRED C57BL; OSTEOARTHRITIS; PLURIPOTENT STEM CELLS;

EID: 84925539085     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38780     Document Type: Article

References (50)

1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al, for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008; 58: 26-35.
2. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al., OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16: 137-62.
3. Hunter DJ,. Pharmacologic therapy for osteoarthritis-the era of disease modification. Nat Rev Rheumatol 2011; 7: 13-22.
4. Bijlsma JW, Berenbaum F, Lafeber FP,. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011; 377: 2115-26.
5. Goldring MB, Marcu KB,. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther 2009; 11: 224.
6. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H,. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Ref Rheumatol 2011; 7: 33-42.
7. Sandell LJ, Xing X, Franz C, Davies S, Chang LW, Patra D,. Exuberant expression of chemokine genes by adult human articular chondrocytes in response to IL-1β. Osteoarthritis Cartilage 2008; 16: 1560-71.
8. Hollander AP, Heathfield TF, Webber C, Iwata Y, Bourne R, Rorabeck C, et al., Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest 1994; 93: 1722-32.
9. Poole AR, Nelson F, Dahlberg L, Tchetina E, Kobayashi M, Yasuda T, et al., Proteolysis of the collagen fibril in osteoarthritis. Biochem Soc Symp 2003: 115-23.
10. Bondeson J, Wainwright S, Hughes C, Caterson B,. The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review [review]. Clin Exp Rheumatol 2008; 26: 139-45.
11. Sandy JD, Flannery CR, Neame PJ, Lohmander LS,. The structure of aggrecan fragments in human synovial fluid: evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest 1992; 89: 1512-6.
12. Setton LA, Elliott DM, Mow VC,. Altered mechanics of cartilage with osteoarthritis: human osteoarthritis and an experimental model of joint degeneration. Osteoarthritis Cartilage 1999; 7: 2-14.
13. Wilusz RE, Zauscher S, Guilak F,. Micromechanical mapping of early osteoarthritic changes in the pericellular matrix of human articular cartilage. Osteoarthritis Cartilage 2013; 21: 1895-903.
14. Chevalier X, Eymard F, Richette P,. Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol 2013; 9: 400-10.
15. Kishore N, Sommers C, Mathialagan S, Guzova J, Yao M, Hauser S, et al., A selective IKK-2 inhibitor blocks NF-κB-dependent gene expression in interleukin-1β-stimulated synovial fibroblasts. J Biol Chem 2003; 278: 32861-71.
16. Fermor B, Weinberg JB, Pisetsky DS, Misukonis MA, Fink C, Guilak F,. Induction of cyclooxygenase-2 by mechanical stress through a nitric oxide-regulated pathway. Osteoarthritis Cartilage 2002; 10: 792-8.
17. Gendron C, Kashiwagi M, Hughes C, Caterson B, Nagase H,. TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors. FEBS Lett 2003; 555: 431-6.
18. Charni-Ben Tabassi N, Desmarais S, Bay-Jensen AC, Delaisse JM, Percival MD, Garnero P,. The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation. Osteoarthritis Cartilage 2008; 16: 1183-91.
19. Chowdhury TT, Bader DL, Lee DA,. Anti-inflammatory effects of IL-4 and dynamic compression in IL-1β stimulated chondrocytes. Biochem Biophys Res Commun 2006; 339: 241-7.
20. Dell'Accio F, De Bari C, Luyten FP,. Molecular markers predictive of the capacity of expanded human articular chondrocytes to form stable cartilage in vivo. Arthritis Rheum 2001; 44: 1608-19.
21. Hojo H, Yano F, Ohba S, Igawa K, Nakajima K, Komiyama Y, et al., Identification of oxytetracycline as a chondrogenic compound using a cell-based screening system. J Bone Miner Metab 2010; 28: 627-33.
22. Yano F, Hojo H, Ohba S, Fukai A, Hosaka Y, Ikeda T, et al., A novel disease-modifying osteoarthritis drug candidate targeting Runx1. Ann Rheum Dis 2013; 72: 748-53.
23. Johnson K, Zhu S, Tremblay MS, Payette JN, Wang J, Bouchez LC, et al., A stem cell-based approach to cartilage repair. Science 2012; 336: 717-21.
24. Yang SL, Harnish E, Leeuw T, Dietz U, Batchelder E, Wright PS, et al., Compound screening platform using human induced pluripotent stem cells to identify small molecules that promote chondrogenesis. Protein Cell 2012; 3: 934-42.
25. Huang AH, Motlekar NA, Stein A, Diamond SL, Shore EM, Mauck RL,. High-throughput screening for modulators of mesenchymal stem cell chondrogenesis. Ann Biomed Eng 2008; 36: 1909-21.
26. Engle SJ, Puppala D,. Integrating human pluripotent stem cells into drug development. Cell Stem Cell 2013; 12: 669-77.
27. Diekman BO, Christoforou N, Willard VP, Sun H, Sanchez-Adams J, Leong KW, et al., Cartilage tissue engineering using differentiated and purified induced pluripotent stem cells. Proc Natl Acad Sci U S A 2012; 109: 19172-7.
28. Carey BW, Markoulaki S, Hanna J, Saha K, Gao Q, Mitalipova M, et al., Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci U S A 2009; 106: 157-62.
29. Grant TD, Cho J, Ariail KS, Weksler NB, Smith RW, Horton WA,. Col2-GFP reporter marks chondrocyte lineage and chondrogenesis during mouse skeletal development. Dev Dyn 2000; 218: 394-400.
30. Stanton H, Golub SB, Rogerson FM, Last K, Little CB, Fosang AJ,. Investigating ADAMTS-mediated aggrecanolysis in mouse cartilage. Nat Protoc 2011; 6: 388-404.
31. Little CB, Mittaz L, Belluoccio D, Rogerson FM, Campbell IK, Meeker CT, et al., ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo. Arthritis Rheum 2005; 52: 1461-72.
32. McNulty AL, Rothfusz NE, Leddy HA, Guilak F,. Synovial fluid concentrations and relative potency of interleukin-1 α and β in cartilage and meniscus degradation. J Orthop Res 2013; 31: 1039-45.
33. Lima EG, Tan AR, Tai T, Bian L, Stoker AM, Ateshian GA, et al., Differences in interleukin-1 response between engineered and native cartilage. Tissue Eng Part A 2008; 14: 1721-30.
34. Estes BT, Diekman BO, Gimble JM, Guilak F,. Isolation of adipose-derived stem cells and their induction to a chondrogenic phenotype. Nat Protoc 2010; 5: 1294-311.
35. Detamore MS, Athanasiou KA,. Effects of growth factors on temporomandibular joint disc cells. Arch Oral Biol 2004; 49: 577-83.
36. McNulty AL, Miller MR, O'Connor SK, Guilak F,. The effects of adipokines on cartilage and meniscus catabolism. Connect Tissue Res 2011; 52: 523-33.
37. Chan PS, Caron JP, Orth MW,. Short-term gene expression changes in cartilage explants stimulated with interleukin 1β plus glucosamine and chondroitin sulfate. J Rheumatol 2006; 33: 1329-40.
38. Christensen SE, Coles JM, Zelenski NA, Furman BD, Leddy HA, Zauscher S, et al., Altered trabecular bone structure and delayed cartilage degeneration in the knees of collagen VI null mice. PLoS One 2012; 7: e33397.
39. Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, et al., Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013; 12: 101-13.
40. Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S, et al., Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011; 473: 221-5.
41. Cherry AB, Daley GQ,. Reprogramming cellular identity for regenerative medicine. Cell 2012; 148: 1110-22.
42. Bellin M, Marchetto MC, Gage FH, Mummery CL,. Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol 2012; 13: 713-26.
43. Caterson B, Flannery CR, Hughes CE, Little CB,. Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol 2000; 19: 333-44.
44. Mohanraj B, Hou C, Meloni GR, Cosgrove BD, Dodge GR, Mauck RL,. A high throughput mechanical screening device for cartilage tissue engineering. J Biomech 2014; 27 47: 2130-6.
45. Ousema PH, Moutos FT, Estes BT, Caplan AI, Lennon DP, Guilak F, et al., The inhibition by interleukin 1 of MSC chondrogenesis and the development of biomechanical properties in biomimetic 3D woven PCL scaffolds. Biomaterials 2012; 33: 8967-74.
46. Marcu KB, Otero M, Olivotto E, Borzi RM, Goldring MB,. NF-κB signaling: multiple angles to target OA. Curr Drug Targets 2010; 11: 599-613.
47. Forsyth CB, Pulai J, Loeser RF,. Fibronectin fragments and blocking antibodies to α2β1 and α5β1 integrins stimulate mitogen-activated protein kinase signaling and increase collagenase 3 (matrix metalloproteinase 13) production by human articular chondrocytes. Arthritis Rheum 2002; 46: 2368-76.
48. Durigova M, Troeberg L, Nagase H, Roughley PJ, Mort JS,. Involvement of ADAMTS5 and hyaluronidase in aggrecan degradation and release from OSM-stimulated cartilage. Eur Cells Mater 2011; 21: 31-45.
49. Stevens AL, Wishnok JS, White FM, Grodzinsky AJ, Tannenbaum SR,. Mechanical injury and cytokines cause loss of cartilage integrity and up-regulate proteins associated with catabolism, immunity, inflammation, and repair. Mol Cell Proteomics 2009; 8: 1475-89.
50. Merkle FT, Eggan K,. Modeling human disease with pluripotent stem cells: from genome association to function. Cell Stem Cell 2013; 12: 656-68.